Global pharma, biometrics team build out

Proclinical Staffing our consultant managing the role
Posting date: 18/01/2021

Global pharma, biometrics team build out

Case study

The overview

A global pharmaceutical company partnered with us to build their in-house biometrics team.

The challenge

Our partner had previously outsourced their biometric work to CROs. However, following a recent investment, they wanted to build and implement an in-house team.

The first key hire that they needed to make was a clinical data manager. They had been actively interviewing candidates for the role for over 4 months with no success. Their location wasn’t proving favourable for candidates and the talent pool of suitable candidates was very limited. The role required the candidate to work onsite, which is atypical of the usual requirements, so added further to the challenge.

We also needed to develop a clear and effective narrative to take to market as our partner was not as well-known in the UK as some of their competitors.

The solution

We delivered this project on a retained search basis. This meant we offered a dedicated, expert project team who had an extensive network of suitable and qualified candidates across the UK and EU. We used our existing network and we utilised specialist recruitment tools such as LinkedIn Recruiter, giving us unrivalled access to the market, and worked with this partner to establish a strong narrative piece. We advised on salary and presented candidates at a variety of cost levels, which were reflective of their respective experiences.

We had weekly meetings with the senior management team, providing regular updates and shortlists, which ensured our partner was always kept informed of how the search was progressing. We had a final shortlist of 6 candidates, of which 4 were interviewed.

The outcome

The final hire was successfully made with a candidate from a top 10 pharmaceutical company

The project was delivered within agreed timeframes and budget

We continue to partner with the organisation across their regulatory affairs division